Sunday 18 October 2026
Export ACIU’s income statement to Excel — free account
AC Immune
ACIU Healthcare Biotechnology
AC Immune’s revenue for fiscal 2025 (year ended December 2025) was $4.3 million, down 86.1% from fiscal 2024. In the quarter to June 2026, revenue grew 29.7%, EPS grew 9.52% and free cash flow grew 4.66%, each against the same quarter a year earlier.
2.39
0.06
−2.45%
Follow ACIU
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
— | 0.00 | 0.00 | 0.00 |
+8 more quarters Free account |
P/S ratio |
— | 58.49 | 73.36 | 62.43 | |
P/FCF ratio |
— | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
— | (15.35) | (17.89) | (12.05) | |
P/B ratio |
— | 6.74 | 5.84 | 3.74 | |
Price to Tangible BV |
— | 0.00 | 0.00 | 19.40 | |
EV/Sales |
— | 38.95 | 48.34 | 33.94 | |
EV/EBITDA |
— | 0.00 | 0.00 | 0.00 | |
EV/Operating CF |
— | (2.16) | (2.49) | (2.63) | |
EV/FCF |
— | (2.13) | (2.46) | (2.58) | |
Quick Ratio |
0.89 | 0.82 | 0.98 | 1.12 | |
Current Ratio |
0.93 | 0.87 | 1.02 | 1.16 | |
Net Debt/EBITDA |
0.00 | 0.00 | 6.23 | 6.99 | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.11 | 0.00 | 0.00 | |
Asset Turnover |
0.00 | 0.04 | 0.02 | 0.02 | |
Operating CF/Net income |
0.00 | 0.00 | 0.96 | 1.22 | |
Capex/Depreciation |
(0.42) | — | (0.13) | (0.12) | |
Interest Coverage |
— | (227.64) | (351.49) | (351.29) | |
Research and Development Expense of Revenue |
— | 1,049.47% | 3,008.27% | 1,391.99% | |
Selling, General and Administrative Expense of Revenue |
— | 373.00% | 1,165.84% | 379.87% | |
Intangible Assets out of Total Assets |
0.34 | 0.00 | 0.33 | 0.29 | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 207.23% | 95.10% | |
Graham Net Nets |
— | (0.12) | (0.05) | 0.02 | |
Graham Number |
— | 0.00 | 0.00 | 0.00 | |
Earnings Yield |
— | (29.82%) | (26.75%) | (29.07%) | |
Free Cash Flow Yield |
— | (31.20%) | (26.76%) | (21.06%) | |
Revenue per Share |
— | 0.01 | 0.00 | 0.01 | |
Operating CF per Share |
0.00 | 0.00 | (0.18) | (0.24) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
0.00 | 0.00 | (0.18) | (0.24) | |
Cash per Share |
0.00 | 0.97 | 1.10 | 1.34 | |
Shareholders Equity per Share |
0.00 | 0.41 | 0.54 | 0.77 | |
Interest Debt per Share |
— | 0.00 | 0.00 | 0.00 | |
Book value per Share |
0.00 | 0.41 | 0.54 | 0.77 | |
Free Cash Flow |
(20.34) | — | (17.78) | (24.30) | |
Working Capital |
(8.65) | (15.56) | 2.45 | 19.32 | |
Capital Expenditures |
(0.54) | — | (0.10) | (0.10) | |
Net Current Asset Value |
(27.62) | (32.97) | (15.26) | 5.73 | |
EV/EBIT |
— | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.00 | 0.00 | 0.21 | 0.08 | |
Price to Operating Income |
— | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
9.48 | 1.92 | 1.22 | 15.70 | |
Average Payables |
2.61 | 2.17 | 2.76 | 1.80 | |
Average Assets |
212.56 | 117.40 | 224.24 | 248.33 | |
Average Common Equity |
67.55 | 72.85 | 90.85 | 114.21 |
Columns are period end dates